Azurrx Biopharma Inc (AZRX) Fundamental Analysis & Valuation
NASDAQ:AZRX
3.45
+0.07 (+2.07%)
At close: Sep 21, 2021
3.42
-0.03 (-0.87%)
After Hours: 9/21/2021, 8:00:01 PM
This AZRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Taking everything into account, AZRX scores 2 out of 10 in our fundamental rating. AZRX was compared to 519 industry peers in the Biotechnology industry. AZRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AZRX has a expensive valuation and it also scores bad on growth.
1. AZRX Profitability Analysis
1.1 Basic Checks
- In the past year AZRX has reported negative net income.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -288.01% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for AZRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. AZRX Health Analysis
2.1 Basic Checks
- There is no outstanding debt for AZRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- AZRX has an Altman-Z score of -18.16. This is a bad value and indicates that AZRX is not financially healthy and even has some risk of bankruptcy.
- There is no outstanding debt for AZRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.16 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- AZRX has a Current Ratio of 1.33. This is a normal value and indicates that AZRX is financially healthy and should not expect problems in meeting its short term obligations.
- A Quick Ratio of 1.33 indicates that AZRX should not have too much problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.33 |
3. AZRX Growth Analysis
3.1 Past
- The earnings per share for AZRX have decreased strongly by -32.56% in the last year.
EPS 1Y (TTM)-32.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, AZRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.05% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.24%
EPS Next 2Y28.65%
EPS Next 3Y20.55%
EPS Next 5Y11.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. AZRX Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for AZRX. In the last year negative earnings were reported.
- Also next year AZRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -0.63 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as AZRX's earnings are expected to grow with 20.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.65%
EPS Next 3Y20.55%
5. AZRX Dividend Analysis
5.1 Amount
- AZRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AZRX Fundamentals: All Metrics, Ratios and Statistics
3.45
+0.07 (+2.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.11%
Inst Owner Change0%
Ins Owners23.96%
Ins Owner Change0%
Market Cap32.17M
Revenue(TTM)N/A
Net Income(TTM)-39.68M
Analysts90
Price Target3.4 (-1.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | -0.63 |
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.75
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -288.01% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.33 | ||
| Altman-Z | -18.16 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.88%
EPS Next Y52.24%
EPS Next 2Y28.65%
EPS Next 3Y20.55%
EPS Next 5Y11.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
Azurrx Biopharma Inc / AZRX FAQ
What is the fundamental rating for AZRX stock?
ChartMill assigns a fundamental rating of 1 / 10 to AZRX.
Can you provide the valuation status for Azurrx Biopharma Inc?
ChartMill assigns a valuation rating of 1 / 10 to Azurrx Biopharma Inc (AZRX). This can be considered as Overvalued.
How profitable is Azurrx Biopharma Inc (AZRX) stock?
Azurrx Biopharma Inc (AZRX) has a profitability rating of 1 / 10.
Can you provide the financial health for AZRX stock?
The financial health rating of Azurrx Biopharma Inc (AZRX) is 2 / 10.